Abstract:Abstract Cancer metabolism is highly heterogenous and flexible with the Warburg effect or oxidative phosphorylation (OXPHOS) prevailing in a cancer type- and context-dependent manner. Past studies have demonstrated that targeting OXPHOS robustly inhibits glycolysis-deficient cancer cell viability and tumorigenicity. However, the therapeutic potential of OXPHOS inhibition in metabolically flexible glycolysis-competent cancers is unclear. Furthermore, whether the depletion of OXPHOS-derived ATP or the abolition of OXPHOS-supported biosynthesis is the major determinant of cancer cell susceptibility remains obscure. To address these questions, we exposed a panel of metabolically flexible glycolysis-competent cancer cell lines to OXPHOS inhibitors and tested cell survival and proliferation. We monitored metabolic phenotypes and changes in metabolites using seahorse metabolic flux assays and targeted metabolomics, respectively. Stable isotope-tracing was carried out with uniformly labelled [15N]-/[13C]-aspartate. Patient-derived xenograft (PDX) models of colorectal cancer in NSG mice were used for in vivo validation. Here we provide evidence that OXPHOS inhibition potently diminishes metabolically flexible glycolysis-competent cancer cell proliferation and tumorigenicity without causing devastating energy stress. The inhibition of cell proliferation by OXPHOS inhibitors is associated with S-phase cell cycle arrest and the enrichment of the G2/M DNA-damage check point regulation pathway, suggestive of replication stress. Indeed, IACS treatment significantly reduces the purine/pyrimidine nucleotide pools, which is primarily caused by aspartate deficiency resulting from a shortage in the electron acceptor NAD+. The supplementation of exogenous nucleosides, aspartate, or pyruvate that can accept electron generating NAD+, into the culture medium rescues cells from IACS-induced cell cycle arrest. Instructively, inhibition of GOT1, which catalyzes cytosolic aspartate biosynthesis when mitochondrial aspartate production is dampened, renders cancer cells grown in two- and three-dimensional cultures more susceptible to OXPHOS inhibition. Collectively, these results indicate that 1) disruption of nucleotide homeostasis is a major determinant of cancer cell susceptibility to OXPHOS inhibition; 2) OXPHOS inhibition is a promising avenue for the treatment of cancers that are metabolic flexible and glycolysis competent; and 3) GOT1 targeting is potentially a useful approach to improve the therapeutic efficacy of OXPHOS inhibition for cancer treatment. Citation Format: Xiaohong Zhao, Yuan Yuan Zhang, Liang Xu, Ting La, Yu Chen Feng, Hai Jie Tang, Ran Xu, Vinod K. Narayana, David P. De Souza, Lake-Ee Quek, Jeff Holst, Rick F. Thorne, Mark Baker, Tao Liu, Lei Jin, Xu Dong Zhang. Disruption of nucleotide homeostasis confers cancer cell susceptibility to oxidative phosphorylation inhibition independently of energy depletion. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 3687.

Multiomics analysis identifies oxidative phosphorylation as a cancer vulnerability arising from myristoylation inhibition

An inhibitor of oxidative phosphorylation exploits cancer vulnerability

NNMT‐DNMT1 Axis is Essential for Maintaining Cancer Cell Sensitivity to Oxidative Phosphorylation Inhibition

N-Myristoytransferase Inhibition Causes Mitochondrial Iron Overload and Parthanatos in TIM17A-Dependent Aggressive Lung Carcinoma

Electron transport chain inhibition increases cellular dependence on purine transport and salvage

N-Myristoylation by NMT1 Is POTEE-Dependent to Stimulate Liver Tumorigenesis via Differentially Regulating Ubiquitination of Targets

Targeting Mitochondrial DNA Transcription by POLRMT Inhibition or Depletion as a Potential Strategy for Cancer Treatment

Abstract C016: Oxidative Phosphorylation is a Metabolic Vulnerability in Chemotherapy Resistant Triple Negative Breast Cancer

Mitochondrial mutations and mitoepigenetics: Focus on regulation of oxidative stress-induced responses in breast cancers

Abstract 3687: Disruption of nucleotide homeostasis confers cancer cell susceptibility to oxidative phosphorylation inhibition independently of energy depletion

NMT1 Inhibition Modulates Breast Cancer Progression Through Stress-Triggered JNK Pathway.

Identification of novel resistance mechanisms to NAMPT inhibition via the de novo NAD+ biosynthesis pathway and NAMPT mutation

Role of MTH1 in oxidative stress and therapeutic targeting of cancer

N-myristoyltransferase proteins in breast cancer: prognostic relevance and validation as a new drug target

Targeting Human Lung Adenocarcinoma with a Suppressor of Mitochondrial Superoxide Production

N-myristoyltransferase-1 is necessary for lysosomal degradation and mTORC1 activation in cancer cells

Multi-Omics Analysis of NCI-60 Cell Line Data Reveals Novel Metabolic Processes Linked with Resistance to Alkylating Anti-Cancer Agents

Cancer resistance and metastasis are maintained through oxidative phosphorylation

An OMA1 redox site controls mitochondrial homeostasis, sarcoma growth, and immunogenicity

Abstract B070: Myc synthetic lethality as a therapeutic strategy for resistance: Insights into the targetability of mitochondrial complex I in Myc-high TNBC

Abstract A52: Overcoming Mitochondrial Oxidative Phosphorylation-Mediated Resistance to Targeted Therapies in Melanoma